Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Clinical trial NCT03591965 · TERMINATED

Trial details

NCT number: NCT03591965
Sponsor: Antengene Therapeutics Limited
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2018-08-07
Primary completion: 2022-08-03
Enrollment: 73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.